Hospital services

Blessing Health System partners with Biofourmis to launch home hospitalization services

The leader in virtual care and remote patient management solutions will enable
integrated health system serving three states to participate in a rural hospital
research study and CMS program of acute hospital care at home

BOSTON, March 30, 2022 /PRNewswire/ — Bioantsa Bostonglobal leader in virtual care and digital therapies, today announced that it has been selected by Blessing Health System in Quincy, a technology solution partner for its new program, which provides acute hospital care in patients’ homes.

Blessing Health System is an integrated rural health system spread across three states (Illinois, Missouri and Iowa) made up of three hospitals, two groups of doctors, an accredited college of nursing and health sciences, a network of specialized medical companies and a charitable foundation.

Biofourmis supports the healthcare system with its turnkey, end-to-end, home hospitalization solution for participation in the Rural House Hospital project. This new program allows caregivers to provide hospital-level care in the home of patients with a range of acute conditions instead of admitting them to a medical facility. This allows them to optimize capacity and ensure hospital beds are available for the most critically ill patients. Other outcomes include greater patient satisfaction, lower readmission rates and hospital-acquired conditions, and reduced overall cost of care. For rural communities, hospital-at-home programs also reduce the travel burden for patients and families and the out-of-pocket costs associated with residential care.

Blessing Health System providers will visit patients in their homes and use Biofourmis technology to monitor them remotely using biosensors and a patient-centric companion app. Data streamed from wearables and electronic patient-reported outcomes (ePRO) is fed into Biofourmis’ artificial intelligence (AI)-powered Biovitals® analysis engine, which establishes a personalized baseline for patients via machine learning and provides real-time notifications to providers. as patient conditions change.

“Participating in a hospital-at-home program in our rural area required choosing an experienced and knowledgeable technology partner that offered a complete solution that we could easily expand as initiatives added more patients and more conditions,” said Marie Frances Barthel, MD, MHCM, SFHM, FACP, Quality and Safety Manager, Blessing Health System. “Although we considered several solutions, Biofourmis offered the most complete, scalable and user-friendly solution. We are convinced that it will allow us to participate successfully in this program, but above all, to offer the care high quality that our patients have come to expect, in the comfort and convenience of their own homes.”

Biofourmis has extensive experience as a technology provider for hospital home care, including the Home Hospital program at Brigham and Women’s Hospital, which co-developed Biofourmis [email protected] technological solutions. Brigham’s clinical leadership has published several clinical studies demonstrating the benefits of its program, including a randomized clinical trial in the Annals of Internal Medicine which found that the Home Hospital program reduced hospital admissions among participating patients by 70% and costs by 40%.

Rural health system of the future
To date, most hospital-at-home programs primarily serve urban areas. Over the next three years, the Rural Home Hospital Project will apply lessons and processes learned from these past initiatives to help build, launch and evaluate a national program to meet the unique care needs of rural residents across the United States. .

The Rural Home Hospital was created by a joint venture between Harvard TJ Chan School of Public Health and Brigham and Women’s Hospital in Massachusetts. Blessing Health System was one of only two US entrants selected from a pool of 700 applicants. The Rural Home Hospital will include patients suffering from acute exacerbations of diseases such as heart failure, chronic obstructive pulmonary disease, asthma, gout, chronic kidney disease and others. For the research study, approximately half of the participants will receive facility-based hospital care and the other half will receive home care.

Blessing Health System is also one of 92 health systems in the nation to receive Acute hospital care at home waiver, with 204 hospitals in 34 participating states (as of the 17th of March). The Acute Hospital Care at Home program provides Medicare 1:1 reimbursement parity for hospitals that admit patients with a wide range of acute conditions to their homes. As with the Rural Home Hospital project, patients receive a combination of in-person and virtual visits from providers, as well as around-the-clock monitoring and communication.

“Health systems in every type of community in the United States are recognizing the clinical and economic benefits of providing safe and effective more home care, whether it is managing chronic acute, post-acute or complex,” said Kuldeep Singh Rajput, CEO. and founder of Biofourmis. “Blessing Health System serves a large geographic region, but by partnering with Biofourmis, together we will ensure that providers have the data and actionable tools to deliver highly personalized care, regardless of where the patients are. patients.

About Biofourmis
Biofourmis is a fast-growing global health technology company focused on leveraging software and data science to deliver virtual care and develop new digital therapies. The company’s robust care management platform, [email protected], enables remote disease management across a range of medical conditions for acute, post-acute and chronic care. The solution uses medical-grade wearable devices to continuously collect patient data, which is analyzed by Biovitals®, Biofourmis’ highly sophisticated and clinically validated predictive analytics engine. With support from Biofourmis’ in-house clinical care team, payers and providers can leverage the solution to predict clinical deterioration before a critical event, enabling earlier interventions for better outcomes and cost savings. costs. Likewise, the company discovers, develops and delivers clinically validated digital therapies. These monotherapies or prescription “pill plus” therapies help payers and providers improve the lives of patients while reducing healthcare utilization and associated costs. For more information visit:; and follow the company on LinkedIn and Twitter.

Media Contact:
Tara Stultz
Amendola Communications for Biofourmis
[email protected]

SOURCE Bioants